Affinity Asset Advisors, LLC Bio Atla, Inc. Transaction History

Affinity Asset Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $246,500 - $445,150	-145,000 Reduced 44.62%	180,000 $306,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $402,499 - $1.44 Million	175,000 Added 116.67%	325,000 $871,000
Q4 2022 Feb 13, 2023	BUY	$6.29 - $11.01 $943,500 - $1.65 Million	150,000 New	150,000 $1.24 Million

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.